Business Context and Reporting Period
Syndax Pharmaceuticals Inc. filed this Form 8-K on May 24, 2017, to report the entry into a material definitive agreement regarding a public offering of common stock. The company is a Delaware corporation headquartered in Waltham, Massachusetts.
Key Financial Metrics and Transaction Details
- Shares Offered: 3,750,000 shares of common stock.
- Offering Price: $13.25 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 562,500 additional shares.
- Expected Net Proceeds: Approximately $46.5 million (excluding over-allotment exercise), after deducting underwriting discounts, commissions, and estimated expenses.
- Expected Closing Date: On or about May 31, 2017.
This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity metrics for the company.
Material Changes
The primary material change is the execution of an underwriting agreement with Morgan Stanley & Co. LLC and Citigroup Global Markets Inc. This transaction represents a significant capital raise intended to fund the company's operations and development programs, though specific allocation of funds is not detailed in this text.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the completion and timing of the offering. Management cautions that actual results may differ materially from projections due to risks and uncertainties, including the satisfaction of customary closing conditions. There is no assurance the offering will be completed on anticipated terms or at all. Investors are directed to the "Risk Factors" sections in the company's other SEC filings and the registration statement for a comprehensive list of risks.
Key Facts for Investor Verification
- Verify the final closing date and whether the underwriters exercised the 30-day over-allotment option.
- Confirm the final net proceeds received after all transaction expenses are settled.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants, indemnification clauses, and lock-up provisions.
- Check subsequent filings for the company's updated cash position and how the proceeds are being utilized.